Communiqués PharmaEssentia Corporation

Actions

6446

TW0006446008

Recherche biotechnologique et médicale

Cours en clôture Taiwan S.E. 25/08/2026			Varia. 5j.	Varia. 1 janv.
1 490,00 ^TWD	+1,02 %		+6,43 %	+251,66 %

17/08	PharmaEssentia Corp dépose des demandes d'extension d'indication pour le Besremi auprès du régulateur taïwanais	MT
13/08	PharmaEssentia apporte des précisions sur les projections de revenus pour 2026	MT

Communiqués

07/07	PharmaEssentia Announces Health Canada Approval of BESREMi(R) (ropeginterferon alfa-2b) for Polycythemia Vera (PV)	AQ
29/06	PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen (ropeginterferon alfa-2b-njft) for Polycythemia Vera	AQ
27/04	Frankfurt Higher Regional Court upholds BESREMi(R) arbitral award in favor of AOP Health	AQ
14/01	FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)	AQ
25/11	PharmaEssentia Announces Publication of Phase 3 SURPASS-ET Results in the Lancet Haematology	AQ
18/08/25	PharmaEssentia to Participate at Morgan Stanley 23rd Annual Global Healthcare Conference	BU
03/06/25	PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms	BU
20/05/25	PharmaEssentia to Present Phase 3 SURPASS-ET Data in Oral Session at 2025 ASCO Annual Meeting	BU
01/04/25	Apeximmune Therapeutics Announces Successful Close of Series A Fundraising Round to Advance Next-Generation Immunotherapies	AQ
04/03/25	PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage	BU
18/02/25	PharmaEssentia Corp. - ICC Arbitral Tribunal rules in favor of AOP Health in arbitration proceedings pertaining to BESREMi	AQ
06/01/25	CORRECTING and REPLACING PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia	BU
02/01/25	PharmaEssentia Reaffirms its Commitment to Robust and Reliable Access to Interferon Therapies Amid Global Supply Challenges	BU
19/12/24	PharmaEssentia to Present at the Annual J.P. Morgan Healthcare Conference on January 16, 2025	BU
05/12/24	PharmaEssentia Appoints Joseph R. Horvat as Global Chief Commercial Officer	BU
25/11/24	PharmaEssentia Announces Nine Data Presentations at ASH Annual Meeting	BU
04/09/24	PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada	BU
23/07/24	PharmaEssentia Appoints Beth A. Krewson as Head of Legal	AQ
02/04/24	PharmaEssentia - ANALYSES FIND PATIENTS WITH POLYCYTHEMIA VERA TREATED WITH BESREMI HAD INCREASED PROBABILITY OF ACHIEVING COMPLETE HEMATOLOGIC RESPONSE	AQ
02/11/23	Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft	BU
03/10/23	PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune Checkpoint Antibody Candidate	BU
18/09/23	PharmaEssentia Included in FTSE Russell Indices	BU
15/09/23	PHARMAESSENTIA AND MPN ADVOCACY AND EDUCATION INTERNATIONAL LAUNCH NEW EDUCATIONAL INITIATIVE TO EMPOWER PEOPLE LIVING WITH POLYCYTHEMIA VERA	AQ
04/08/23	New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera	BU
30/06/23	New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May Achieve Greater and Quicker Complete Hematologic and Molecular Responses in Polycythemia Vera	BU